Amarin Corp Plcuk (AMRN) Equity Average (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Equity Average of $454.3 million for Q1 2026, down 5.33% year-over-year from $479.9 million in Q1 2025, and down 1.03% quarter-over-quarter from $459.1 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Equity Average (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Equity Average data on file, last reported at $454.3 million in Q1 2026.
- Equity Average for Q1 2026 came in at $454.3 million, down 5.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $454.3 million (down 5.33% YoY), and the FY2025 annual result was $472.7 million, down 8.94% from the prior year.
- Equity Average declined to $454.3 million in Q1 2026 per AMRN's latest filing, from $459.1 million in the prior quarter.
- Over five years, Equity Average peaked at $654.1 million in Q1 2022 and troughed at $454.3 million in Q1 2026.
- A 5-year average of $540.8 million and a median of $549.0 million in 2024 frame the typical range for Equity Average.
- The sharpest annual moves came in 2022 and 2025: Equity Average climbed 3.65% in 2022, then slipped 14.72% in 2025.
- A 5-year view of Equity Average shows it stood at $591.6 million in 2022, then retreated by 6.59% to $552.6 million in 2023, then decreased by 7.93% to $508.8 million in 2024, then declined by 9.77% to $459.1 million in 2025, then dropped by 1.03% to $454.3 million in 2026.
- Business Quant data shows AMRN's Equity Average at $454.3 million in Q1 2026, $459.1 million in Q4 2025, and $461.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 454.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 454.35 Mn |
| Dec 31, 2025 | 459.09 Mn |
| Sep 30, 2025 | 461.91 Mn |
| Jun 30, 2025 | 469.31 Mn |
| Mar 31, 2025 | 479.93 Mn |
| Dec 31, 2024 | 508.78 Mn |
| Sep 30, 2024 | 541.63 Mn |
| Jun 30, 2024 | 548.91 Mn |
| Mar 31, 2024 | 549.02 Mn |
| Dec 31, 2023 | 552.62 Mn |
| Sep 30, 2023 | 561.14 Mn |
| Jun 30, 2023 | 576.96 Mn |
| Mar 31, 2023 | 590.06 Mn |
| Dec 31, 2022 | 591.58 Mn |
| Sep 30, 2022 | 583.94 Mn |
| Jun 30, 2022 | 610.58 Mn |
| Mar 31, 2022 | 654.10 Mn |
| Dec 31, 2021 | 654.80 Mn |
| Sep 30, 2021 | 643.91 Mn |
| Jun 30, 2021 | 639.97 Mn |